PT-141 (bremelanotide): side effects, timing, and the evidence

PT-141, bremelanotide, works on melanocortin receptors in the central nervous system. It was developed and trialled for hypoactive sexual desire disorder in premenopausal women, which is the population the evidence describes. Male use is off-label and thinly studied.

Sexual Health

Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.

The Short Version

  • PT-141 and bremelanotide are the same molecule; PT-141 is the development code, bremelanotide the drug name.
  • It is a melanocortin receptor agonist acting on central nervous system pathways involved in sexual desire, not a blood-flow drug like the PDE5 inhibitors.1
  • The RECONNECT trials enrolled premenopausal women with acquired, generalised hypoactive sexual desire disorder. That is the population the efficacy and safety data describe.2
  • Use in men is off-label, and the supporting evidence is far thinner than the female HSDD dataset.3
  • Side effects and duration: in the Vyleesi label's placebo-controlled trials, nausea affected 40.0% of women versus 1.3% on placebo, usually starting within an hour and lasting about two hours, and the label states that how long the benefit lasts after a dose is unknown.4

What PT-141 is

PT-141 is bremelanotide, a synthetic cyclic heptapeptide derived from melanotan II, which was itself derived from alpha-melanocyte-stimulating hormone. Melanotan II was being investigated for tanning when researchers noticed an unexpected effect on sexual arousal in study participants. That observation is the origin of this entire drug program.

Bremelanotide was refined from that lineage to keep the sexual-response effect while reducing the pigmentation activity, and it is administered by subcutaneous injection on demand rather than daily.

The categorical difference from sildenafil or tadalafil matters. PDE5 inhibitors act peripherally on smooth muscle and blood flow; they help the physical response happen when desire and arousal are already present. Bremelanotide acts centrally, upstream, on the pathways that generate desire itself. The two address different failure points, and one is not a substitute for the other.

PT-141 side effects

The figures in this section come from Vyleesi, the FDA-approved bremelanotide autoinjector, studied in 1247 premenopausal women with acquired, generalized HSDD in two 24-week placebo-controlled trials.4 Compounded bremelanotide is not FDA-approved, and it is not what those trials measured. Versus placebo, the most common reactions were nausea (40.0% vs 1.3%), flushing (20.3% vs 0.3%), injection site reactions (13.2% vs 8.4%), headache (11.3% vs 1.9%) and vomiting (4.8% vs 0.2%).4 The discontinuation rate due to adverse reactions was 18% on Vyleesi and 2% on placebo.4

Nausea had a median onset within one hour of the dose and lasted about two hours.4 It was highest after the first dose (21% of patients) and fell to about 3% after later doses.4 Thirteen percent of treated patients received an anti-emetic, and 8% left the trials because of nausea.4 Oral ondansetron taken 30 minutes beforehand did not reduce nausea in a separate single-dose study, and the label says it is not recommended.4 For persistent or severe nausea, the label says to consider discontinuing.4

Blood pressure rose and heart rate fell after each dose, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic and a heart rate reduction of up to 5 beats per minute.4 Focal hyperpigmentation, including the face, gingiva and breasts, was reported in 1% of patients using up to 8 doses a month and in no placebo patients, and resolution was not confirmed in all patients.4

The label lists uncontrolled hypertension and known cardiovascular disease as contraindications.4 It also says to avoid using it with oral naltrexone products for alcohol or opioid addiction, because bremelanotide may significantly decrease naltrexone exposure, and that it may slow gastric emptying and affect absorption of other oral medicines.4

How long PT-141 takes to work and how long it lasts

On duration, the Vyleesi label is plain: the duration of efficacy after each dose is unknown, and the optimal window for administration has not been fully characterized.4 There is therefore no label figure for how many hours the effect on desire lasts. The label tells patients to inject at least 45 minutes before anticipated sexual activity, and says they may choose their timing based on how they experience the duration of effect and any nausea.4

What was measured is the drug in the body. Median time to peak plasma concentration was about 1.0 hour (range 0.5 to 1.0 hours), and mean terminal half-life was about 2.7 hours (range 1.9 to 4.0 hours).4 Blood pressure increases peaked between 2 and 4 hours after the dose and usually returned to baseline within 12 hours.4 The label also says not to take more than one dose within 24 hours, and that more than 8 doses per month is not recommended.4

These are blood levels and vital signs, not a measure of how long desire improves. They describe the approved autoinjector in premenopausal women, not compounded bremelanotide and not men, whose use is off-label.

The melanocortin mechanism

Bremelanotide is a nonselective agonist at melanocortin receptors, with the MC4 receptor thought to be the primary route for its sexual effects.1 MC4 receptors are distributed across hypothalamic and limbic regions involved in appetite, arousal, and motivated behavior.

Work on the neurobiology of bremelanotide for hypoactive sexual desire disorder describes activation of central pathways implicated in sexual desire, including effects on dopaminergic transmission in the medial preoptic area, a region with a long history in the animal literature on sexual motivation.1

Two implications follow. First, this is a brain drug, and its side-effect profile reflects that: nausea and flushing are consequences of central and systemic melanocortin activation, not incidental. Second, because the melanocortin system is nonselective in its distribution, effects on pigmentation and appetite are mechanistically expected rather than surprising.

The on-demand dosing schedule follows from the pharmacology. It is taken before anticipated sexual activity, typically at least 45 minutes ahead, rather than accumulated daily. That makes it usable episodically and means there is no daily exposure to build up over months.

The RECONNECT trials and who was in them

The pivotal evidence comes from the RECONNECT program, two identical randomized placebo-controlled trials with an open-label extension, reported as long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.2

The enrolled population is the crucial detail. Participants were premenopausal women with acquired, generalised HSDD: acquired meaning the desire loss developed after a period of normal function, generalised meaning it was not confined to one partner or situation. Women whose low desire was attributable to relationship problems, another medical condition, or medication were screened out.

Results showed statistically significant improvements over placebo in desire and in distress associated with low desire, sustained through the open-label extension.2 The effect sizes were modest. This is the recurring, honest finding across HSDD drug development: real separation from placebo, on a distress-weighted subjective endpoint, with a large placebo response and a moderate drug effect.

Nausea was the most common adverse event and the leading cause of discontinuation, along with flushing, headache, and injection-site reactions.2 Transient blood pressure increases and heart rate decreases occurred after dosing, which is why the drug is not appropriate for people with uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation can occur, particularly with frequent use, which is a direct consequence of the melanocortin mechanism.

An independent evaluation of bremelanotide injection for HSDD reviews the same data and reaches a consistent position: a genuine option with a modest effect, a meaningful nausea burden, and a defined population.3

Use in men is off-label

PT-141 is widely discussed and widely sold for men, and this needs saying without hedging: use in men is off-label. The approval and the pivotal evidence concern premenopausal women with HSDD.

There is a real history behind male interest. Bremelanotide was originally developed for erectile dysfunction, including intranasal formulations, and early studies did show erectogenic effects. That program was discontinued, substantially because of blood pressure increases observed with the intranasal route, and the drug was redirected toward female HSDD.3

So the male data is not nonexistent, it is early-phase, older, and belongs to a development path that was abandoned for safety reasons in that formulation. It is not equivalent to the RECONNECT dataset. There is no large randomized trial establishing efficacy and long-term safety of subcutaneous bremelanotide for male low desire or erectile dysfunction.

Off-label prescribing is legal and routine in US medicine and often appropriate. What it requires is that the prescriber and the patient both know the label status, know the evidence is thinner, and screen for the cardiovascular contraindications that the female data made clear. Compounded bremelanotide dispensed through a telehealth program is not an FDA-approved product; it is prepared for an individual patient by a state-licensed US compounding pharmacy on a physician's prescription.

Practical considerations

Dosing is on demand by subcutaneous injection ahead of anticipated activity, with a limit on how often it should be used in a 24-hour period and per month. Those limits exist because of the blood pressure response and the cumulative pigmentation risk, and they are not arbitrary.

Expectation-setting matters more here than with most drugs. HSDD is not a single-mechanism condition. Relationship context, sleep, stress, depression, medication effects, particularly SSRIs, and hormonal status all contribute, and a melanocortin agonist addresses none of them. The trials excluded participants whose low desire had an identifiable alternative cause precisely because the drug is not expected to fix those.

The most useful way to hold it: a real pharmacological option with a modest, measurable effect in a defined population, with a side-effect profile dominated by nausea, and best used inside a broader evaluation rather than as a standalone answer to a complicated question.

Erectile drugs solve a plumbing problem. PT-141 was built for a signalling problem, which is a harder thing to measure and a harder thing to promise.

Astra Editorial

Frequently asked questions

Is PT-141 the same as bremelanotide?

Yes. PT-141 is the development code and bremelanotide is the drug name for the same melanocortin receptor agonist.

How is PT-141 different from Viagra or Cialis?

PDE5 inhibitors act peripherally on blood flow. Bremelanotide acts centrally on melanocortin receptors in brain pathways involved in sexual desire. They address different problems.

Does PT-141 work for men?

Use in men is off-label. The pivotal RECONNECT evidence is in premenopausal women with acquired, generalised HSDD. Earlier male studies existed in a development program that was discontinued, partly over blood pressure concerns with the intranasal formulation.

What are the main side effects?

Nausea is the most common and the leading reason people stop, along with flushing, headache, and injection-site reactions. Transient blood pressure increases mean it is not suitable for people with uncontrolled hypertension or known cardiovascular disease.

How long does PT-141 last?

The FDA label for Vyleesi, the approved bremelanotide autoinjector, states that the duration of efficacy after each dose is unknown. What it does measure is a mean terminal half-life of about 2.7 hours, and blood pressure and heart rate usually back to baseline within 12 hours. Those figures come from premenopausal women with HSDD, not from compounded bremelanotide or from men.

How long does PT-141 take to work?

The FDA label for Vyleesi tells patients to inject at least 45 minutes before anticipated sexual activity. Median time to peak plasma concentration was about 1.0 hour. Those describe the label's dosing instruction and drug levels in premenopausal women, and compounded bremelanotide was not what was measured.

Does PT-141 raise blood pressure?

Yes, temporarily. In the FDA label for Vyleesi, each dose raised systolic pressure by up to 6 mmHg and diastolic by up to 3 mmHg, peaking 2 to 4 hours after the dose, with heart rate down by up to 5 beats per minute. Pressure usually returned to baseline within 12 hours. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications. These figures come from premenopausal women using the approved autoinjector.

References

  1. Review Pfaus JG, Sadiq A, Spana C, et al.. “The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women” CNS Spectrums, 2022.
  2. Human RCT Simon JA, Kingsberg SA, Portman D, et al.. “Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder” Obstetrics and Gynecology, 2019.
  3. Review Cipriani S, Alfaroli C, Maseroli E, et al.. “An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder” Expert Opinion on Pharmacotherapy, 2023.
  4. Reference US Food and Drug Administration. “Vyleesi (bremelanotide injection) prescribing information, NDA 210557, label effective November 13, 2025” DailyMed, National Library of Medicine, 2025.

Where to start

Compounded PT-141 — online evaluation. Only charged if prescribed. Because of the blood pressure response and the off-label status in men, this belongs inside a physician evaluation that screens your cardiovascular history rather than a checkout page.

Start an online evaluation

This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.